Tratamento de Vários Ttipos de Tumores Sólidos com Infusão Contínua, Intrarterial, de Solução de “Methotrexate” Associada à Administração Simultânea e Descontínua do Fator Citrovorum e Complementação pela Telecobaltoterapia

• Autor(a) principal: Silva, M. Santos
• Data de Publicação: 2023
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista Brasileira de Cancerologia (Online)
• Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/3746
• topic: Metotrexato/uso terapêutico; Metotrexato/análise; Neoplasias/tratamento farmacológico; Neoplasias/terapia; Methotrexate/therapeutic use; Methotrexate/analysis; Neoplasms/drug therapy; Neoplasms/therapy; Metotrexato/uso terapéutico; Metotrexato/análisis; Neoplasias/tratamiento farmacológico; Neoplasias/terapia

The intra-arterial infusion of Methotrexate is extremely usefull in the treatment of advanced head and neck cancer. We have obtained complete regression of the tumor in two patiens with far advanced carcinoma of the antrum and in one with squamous cell carcinoma of the tongue. One of the patients is still living and without evidence of disease after 24 months of a single intra-arterial infusion of 125 mg. of Methotrexate complement by local telecobaltotherapv. This person is now in the 5th month of a normal pregnancy. Another patient with the same type of neoplasm had complete remission of the disease and died 15 months later of unrelated disease. Paliation of variable duration was obtained in 60% of the cases, but in 20% of the patients it lasted less than a month. In this trial treatment, conservative doses were employed due to the difficulty of obtaining injectable MXT and C. F. in this country and to the high cost of the treatment which makes it almost impracticable in Brasil at the present time. We feel that with higher doses of MXT we could better our end results. On the other hand, the best responses were achieved in patients treated which 125 mg. of MXT givens in five days. Although MXT may enchance the effects of radiation we were interested when we have associated both treatments in the sommation of effects rather than in enbancement. From our experience, telecobaltotherapy is a necessary complement of intra-arterial MXT therapy which permits consolidation of the good initial results that otherwise are of only a short duration.